Back to UBS Group AG UBS Group AG

NSRXNSRX
4 quarters

Position history for UBS Group AGUBS Group AG's holdings in NASUS PHARMA LTD

No. Ubs exited its NSRX (Nasus Pharma) position in Q2 2026. Its Q1 2026 13F listed 3,094 shares worth $6,869. Ubs first reported NSRX in Q3 2025 and held it in 3 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$8,253

Total Shares Change

-1,241

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Exited
0
-100.0%
$00.0%$3.50
0
2026-Q1
Increased
3,094
+718.5%
$6,8690.0%$2.22
18
2025-Q4
Decreased
378
-69.5%
$3,4590.0%$9.15
0
2025-Q3
New
1,241
-
$8,2530.0%$6.65
25

Other major holders of NSRX: BALYASNY ASSET MANAGEMENT L.P., Hudson Bay Capital Management LP, HRT FINANCIAL LP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used